GNTA vs. ENTX, CDTX, LENZ, ALGS, IKNA, AVRO, TSBX, ELUT, ATRA, and TIL
Should you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Entera Bio (ENTX), Cidara Therapeutics (CDTX), LENZ Therapeutics (LENZ), Aligos Therapeutics (ALGS), Ikena Oncology (IKNA), AVROBIO (AVRO), Turnstone Biologics (TSBX), Elutia (ELUT), Atara Biotherapeutics (ATRA), and Instil Bio (TIL). These companies are all part of the "biological products, except diagnostic" industry.
Entera Bio (NASDAQ:ENTX) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.
Entera Bio's return on equity of 0.00% beat Genenta Science's return on equity.
Entera Bio currently has a consensus price target of $10.00, suggesting a potential upside of 298.41%. Genenta Science has a consensus price target of $25.00, suggesting a potential upside of 676.40%. Given Entera Bio's higher possible upside, analysts plainly believe Genenta Science is more favorable than Entera Bio.
Entera Bio has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.
In the previous week, Entera Bio had 5 more articles in the media than Genenta Science. MarketBeat recorded 11 mentions for Entera Bio and 6 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.99 beat Entera Bio's score of 0.26 indicating that Entera Bio is being referred to more favorably in the media.
14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 8.9% of Entera Bio shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Entera Bio received 168 more outperform votes than Genenta Science when rated by MarketBeat users. However, 85.71% of users gave Genenta Science an outperform vote while only 66.92% of users gave Entera Bio an outperform vote.
Entera Bio has higher revenue and earnings than Genenta Science.
Summary
Genenta Science beats Entera Bio on 7 of the 13 factors compared between the two stocks.
Get Genenta Science News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genenta Science Competitors List
Related Companies and Tools
